1D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91 : 4082-4085.
2Junquera F, Saperas E, de Torres I,et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol, 1999,94: 1070-1076.
3Ozawa CR, Banff A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest,2004, 113:516-527.
4Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet, 1998, 352: 1586-1589.
5Bauditz J, Schachschal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut, 2004, 53: 609-612.
6Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos, 1989,17: 402-405.
7Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with yon Willebrand's disease. Br J Haematol, 2000, 108: 524-527.
8Orlandi M, Inauen W. Chronic gastrointestinal bleeding. Ther Umsch, 2006, 63:327-332.
9Chao CC, Ng Jao YT, Mo LR. Capsule endoscopy for gastrointestinal bleeding with an obscure etiology. J Formos Med Assoe, 2005,104:659-665.
10Bonomini M, Sirolli V, Milano A, et al. Angiodysplasia oi the small bowel: a possible cause of anemia even in mild chronic renal failure. Ghal Nefrol, 2005,22: 171-176.
